Zobrazeno 241 - 250
of 12 818
pro vyhledávání: ''
Publikováno v:
Cancer Discovery. 10:922-934
Aberrant MET signaling can drive tumorigenesis in several cancer types through a variety of molecular mechanisms including MET gene amplification, mutation, rearrangement, and overexpression. Improvements in biomarker discovery and testing have more
Autor:
Franklin W. Huang, Pablo Tamayo, Thomas R. Cech, Josh Lewis Stern, Sarah E. Ferrara, James C. Costello, Kevin Hu, Grace Hibshman, William Kim
Publikováno v:
Mol Cancer Res
Molecular cancer research : MCR, vol 18, iss 7
Molecular cancer research : MCR, vol 18, iss 7
In a substantial fraction of cancers TERT promoter (TERTp) mutations drive expression of the catalytic subunit of telomerase, contributing to their proliferative immortality. We conducted a pan-cancer analysis of cell lines and find a TERTp mutation
Autor:
Hao Huang, Yanrong Ji, Guangyuan Zhao, Jianjun Chen, Edward J. Tanner, Manoj Kandpal, Anusha Chaparala, Yinu Wang, Ramana V. Davuluri, Daniela Matei, Horacio Cardenas
Publikováno v:
Cancer Research. 80:3200-3214
N6-Methyladenosine (m6A) is the most abundant modification of mammalian mRNAs. RNA methylation fine tunes RNA stability and translation, altering cell fate. The fat mass- and obesity-associated protein (FTO) is an m6A demethylase with oncogenic prope
Autor:
Mingjing He, Zhihua Liu, Yong Wan, Rui Zhu, Kun-Liang Guan, Honghong Zhou, Ivet Bahar, Luca Ponzoni, Aiping Luo, Yi Huang, Zhuan Zhou
Publikováno v:
Cancer Res
EIF3H is presumed to be a critical translational initiation factor. Here, our unbiased screening for tumor invasion factors has identified an unexpected role for EIF3H as a deubiquitylating enzyme that dictates breast tumor invasion and metastasis by
Autor:
Joshua J. Gruber, Kirsten Timms, Nadine Tung, Vered Stearns, Daniel P. Silver, Andrea L. Richardson, Ryan Bernhisel, Judy Garber, Shaveta Vinayak, James M. Ford, Melinda L. Telli, Virginia G. Kaklamani, Chris Neff, Steven J. Isakoff, Sunil Badve, William J. Gradishar, Sylvia Adams, Roisin M. Connolly, Charles Chu
Publikováno v:
Clinical Cancer Research. 26:2704-2710
Purpose: Patients with triple-negative breast cancer (TNBC) with homologous recombination deficient tumors achieve significantly higher pathologic complete response (pCR) rates when treated with neoadjuvant platinum-based therapy. Tumor-infiltrating
Publikováno v:
Molecular Cancer Research. 18:835-846
Through the use of an unbiased, genome-scale CRISPR modifier screen, we identified NF1 suppression as a mechanism of resistance to EGFR inhibition in NRAS/KRAS/BRAFV600-wild-type colorectal cancer cells. Reduced NF1 expression permitted sustained sig
Autor:
Yao-Ping Lu, Christina N. Ramirez, Yuqing Yang, Rasika Hudlikar, Ah-Ng Tony Kong, Davit Sargsyan, Irene Yang, Ran Yin, Hsiao-Chen Dina Kuo, Renyi Wu, Lujing Wang, Shanyi Li, David Cheng
Publikováno v:
Cancer Prev Res (Phila)
Sulforaphane (SFN), a potent antioxidant and antiinflammatory agent, has been shown to protect against cancers especially at early stages. However, how SFN affects UVB-mediated epigenome/DNA methylome and transcriptome changes in skin photodamage has
Autor:
Juntao Zou, Liang Zhu, Vineeth Sukrithan, Hongling Zhao, Cari Nicholas, Niloy J. Iqbal, Cindy Yu, Joseph Locker, Edward L. Schwartz, Yingjiao Xue
Publikováno v:
Cancer Research. 80:2355-2367
The RB1 tumor suppressor gene is mutated in highly aggressive tumors including small-cell lung cancer (SCLC), where its loss, along with TP53, is required and sufficient for tumorigenesis. While RB1-mutant cells fail to arrest at G1–S in response t
Autor:
Yutaka Suzuki, Kuniko Horie-Inoue, Hidetaka Kawabata, Takashi Suzuki, Kazuhiro Ikeda, Satoshi Inoue, Yuichi Mitobe, Kenjiro Aogi, Kaori Iino, Ken-ichi Takayama
Publikováno v:
Cancer Research. 80:2230-2242
Endocrine therapy is standard treatment for estrogen receptor (ER)-positive breast cancer, yet long-term treatment often causes acquired resistance, which results in recurrence and metastasis. Recent studies have revealed that RNA-binding proteins (R
Autor:
Natasha Rekhtman, Marc Ladanyi, Hiroki Sato, Daisuke Kubota, Maria E. Arcila, Jason C. Chang, Dana Pe'er, Paul K. Paik, Adam J. Schoenfeld, Hira Rizvi, Helena A. Yu, Monika A. Davare, Romel Somwar, Michael Offin, Yahya Daneshbod, Ujwal Shinde, Mark G. Kris, Joseph M. Chan, Gregory J. Riely
Publikováno v:
Clinical Cancer Research. 26:2654-2663
Purpose: Patterns of resistance to first-line osimertinib are not well-established and have primarily been evaluated using plasma assays, which cannot detect histologic transformation and have differential sensitivity for copy number changes and chro